This review found that modified-release dipyridamole with aspirin was better than aspirin in people with a history of stroke or transient ischaemic attack. The review was well conducted. The reproducibility and generalisability of the results may be limited by the small number of trials and their differences in outcomes reported and treatments applied.
Mean follow-up time ranged from 1.9 to 3.5 years. Mean ages ranged from 62.5 to 66.7 years. Most patients were male (range: 58% to 72% male) and most were hypertensive (range: 51.5% to 74%). Numbers of current smokers ranged from 21% to 36.5% and patients with diabetes from 15.3% to 28%. Two reviews performed the study selection independently; discrepancies were resolved by consensus or consultation with a third reviewer.
Assessment of study quality
Trial quality was assessed in terms of randomisation, baseline comparability of trial arms, eligibility criteria, blinding, withdrawals and outcome reporting. Quality was assessed by two reviewers independently and checked by a third.
Data extraction
Data was extracted on a range of vascular outcomes, according to what was reported in each trial, including: all cause mortality; vascular mortality and incidence of stroke; transient ischaemic attack; and myocardial infarction. Data on the numbers of events in each arm were extracted and results reported as either a relative risk (RR), odds ratio (OR), relative risk reduction (RRR) or hazard ratio (HR) with corresponding 95% confidence intervals (CIs). Individual-level data on clopidogrel was made available by the manufacturer and included in the analysis.
Two reviewers independently extracted data. The process was checked by a third reviewer.
Methods of synthesis
Results from trials were reported in tables and a narrative description of the results undertaken. To compare treatments, pooled relative risks, odds ratios, relative risk reductions or hazard ratios (with 95% confidence intervals) were calculated using a Bayesian, fixed-effect, mixed treatment comparison model. Direct comparisons were not possible due to the differences in treatments used and outcomes reported across trials. Results from these indirect comparisons were compared with the results within individual trials. Separate analyses were performed in different populations (patients with prior stroke; patients with prior myocardial infarction or established peripheral artery disease).
Results of the review
Four trials were included with 48,855 patients. Trial size ranged from 2,736 to 20,332. Two trials assessed clopidogrel, one modified-release dipyridamole alone and three modified-release dipyridamole combined with aspirin. All trials were judged to be of good quality; one trial was open-label.
The CAPRIE trial found that clopidogrel was more effective than aspirin at preventing first vascular events (RRR 8.7, 95% CI 0.3 to 16.5), but found no significant results for any other outcomes.
The ESPS-2 trial found that modified-release dipyridamole with aspirin was more effective than aspirin alone (RR 0.76, 95% CI 0.63 to 0.93) and modified-release dipyridamole alone (RR 0.75, 95% CI 0.61 to 0.91) at preventing stroke. For some secondary outcomes, modified-release dipyridamole alone was no different to aspirin alone.
The ESPRIT trial found that modified-release dipyridamole with aspirin was more effective than aspirin alone at preventing first vascular events (HR 0.80, 95% CI 0.66 to 0.98) and composite outcomes where this was a component.
The PRoFESS trial found no significant difference between clopidogrel and modified-release dipyridamole with aspirin for preventing recurrent stroke, but found a significant benefit of modified-release dipyridamole with aspirin for preventing new or worsening congestive heart failure, and a benefit of clopidogrel for incidence of intercranial haemorrhage. Analysis of individual-level data found that clopidogrel reduced the risk of vascular events in people with multivascular disease (RRR 14.9, 95% CI 0.3 to 27.3).
In patients with prior stroke/transient ischaemic attack, the mixed-treatment comparison models found no evidence of differences between any of the treatments for the prevention of first ischaemic stroke, myocardial infarction, vascular death or all-cause mortality. There was evidence that clopidogrel was more effective than aspirin at preventing recurrent stoke (RR 0.752, 95% CI 0.60 to 0.92). Modified-release dipyridamole with aspirin was similarly also more effective than aspirin alone (RR 0.764, 95% CI 0.62 to 0.92). Clopidogrel reduced the risk of major bleeding compared with aspirin (RR 0.596, 95% CI 0.36 to 0.89). No mixed-treatment analysis was performed in patients with myocardial infarction or established peripheral artery disease.
Cost information
A full systematic review of cost-effectiveness was undertaken, using a similar process to the review of clinical effectiveness. Cost-effectiveness models were fitted. The authors concluded that for patients with ischaemic stroke, clopidogrel was most cost-effective followed by modified-release dipyridamole with aspirin, then aspirin. For patients with peripheral artery disease or multivascular disease, clopidogrel then aspirin were most cost effective. For patients with myocardial infarction, aspirin was most cost-effective followed by clopidogrel.
